AZD 4831

Drug Profile

AZD 4831

Alternative Names: AZD4831

Latest Information Update: 10 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Mayo Clinic
  • Class Cardiotonics; Cardiovascular therapies; Small molecules
  • Mechanism of Action Peroxidase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Heart failure

Most Recent Events

  • 01 Jul 2018 Phase-I/II clinical trials in Heart failure in USA (PO, Capsule) (NCT03611153)
  • 22 Nov 2017 AstraZeneca completes a phase-I clinical trials in Heart failure (In volunteers) in USA (PO) (NCT03136991)
  • 15 May 2017 Phase-I clinical trials in Heart failure (In volunteers) in USA (PO) (NCT03136991)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top